News for BB Biotech AG (BBZA.F)

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one... | February 24, 2021

DGAP-News: BB BIOTECH AG / Key word: Annual Results/Dividend BB Biotech AG publishes its 2020 annual report 19.02.2021 / 07:00 The issuer is solely responsible for the content... | February 19, 2021

DGAP-Ad-hoc: BB BIOTECH AG / Parola : Risultato annuo BB Biotech AG chiude in utile l'esercizio 2020 2021-01-22 / 07:00 CET/CEST Comunicazione d'informazioni privilegiate ai sensi dell'articolo 17... | January 22, 2021

Presidente eletto Biden potrebbe risultare sotto pressione per portare avanti la riforma dei prezzi dei farmaci. Ma in un anno in cui l'attenzione principale sar rivolta alle strategie per... | January 22, 2021

DGAP-News: BB BIOTECH AG / Parola : Risultato annuo/Dividendi BB BIOTECH AG: I vaccini tracciano la strada per uscire dalla pandemia - Il CdA di BB Biotech propone un aumento del dividendo a CHF... | January 22, 2021

Thomas Egger, [email protected] www.bbbiotech.com Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in... | January 22, 2021

DGAP-News: BB BIOTECH AG / Key word: Annual Results/Dividend BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed 2021-01-22 / 07:00 The issuer is... | January 22, 2021

DGAP-Ad-hoc: BB BIOTECH AG / Key word: Annual Results BB Biotech AG closes the 2020 fiscal year with a profit 22-Jan-2021 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17... | January 22, 2021